Venture
VITL secures $7.5M amid GLP-1 surge to transform cash-pay clinic prescriptions
VITL raises $7.5M to modernise cash-pay clinic prescribing, leveraging the rapid growth of GLP-1 treatments and digital healthcare solutions.
1 article
VITL raises $7.5M to modernise cash-pay clinic prescribing, leveraging the rapid growth of GLP-1 treatments and digital healthcare solutions.
Written by the reporters who cover each beat. Unsubscribe in one click.